News

These in vivo and in vitro findings may help guide the future clinical development of Amplimexon, which recently entered a phase I/II study in combination with gemcitabine (Eli

Data from both phase II and phase III clinical trials evaluated the following four compounds: MTS, SPD503 and NRP104, all for the treatment of ADHD, and SPD476 for

Reata has initiated a preclinical development program with peloruside A, the first identified compound in the class, which could enter clinical testing as early as 2007. Peloruside A

Entocort EC (budesonide) is a topical glucocorticosteriod, working primarily in the intestines. It is the only pharmacological product indicated for the treatment of mild to moderate Crohn’s disease

Gross profit from continuing operations was $2.8 million or 56% during the first quarter of 2009 compared to $3.6 million or 58% during the comparable period of 2008.

The company has already begun efficacy and safety studies of its RNA interference (RNAi)-based therapeutic treatment in anaimals models to facilitate its FDA application. Benitec believes it is

Under the agreement, Dowpharma’s proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen’s prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein

The drug was well tolerated and demonstrated potent antiviral activity in a phase I clinical trial involving 34 patients with chronic genotype 1 hepatitis C virus infection. The

The fill/finish plant bought from BioReliance Corporation, a subsidiary of Invitrogen Corporation, will be used to develop and expand Acambis’ vaccine range covering smallpox, West Nile disease and